{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Akt+Inhibitor+MK2206&page=2", "query": { "intervention": "Akt Inhibitor MK2206", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 36, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Akt+Inhibitor+MK2206&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Akt+Inhibitor+MK2206&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T06:36:20.518Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01802320", "title": "Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colon Mucinous Adenocarcinoma", "Colon Signet Ring Cell Adenocarcinoma", "Rectal Mucinous Adenocarcinoma", "Rectal Signet Ring Cell Adenocarcinoma", "Recurrent Colon Carcinoma", "Recurrent Rectal Carcinoma", "Stage IIIA Colon Cancer", "Stage IIIA Rectal Cancer", "Stage IIIB Colon Cancer", "Stage IIIB Rectal Cancer", "Stage IIIC Colon Cancer", "Stage IIIC Rectal Cancer", "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVB Colon Cancer", "Stage IVB Rectal Cancer" ], "interventions": [ { "name": "Akt Inhibitor MK2206", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2013-03", "completion_date": "2015-08-05", "has_results": true, "last_update_posted_date": "2019-09-20", "last_synced_at": "2026-10-04T06:36:20.518Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01802320" }, { "nct_id": "NCT01235897", "title": "MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Tumors", "Cancer" ], "interventions": [ { "name": "MK-2206", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2011-03", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2014-04-17", "last_synced_at": "2026-10-04T06:36:20.518Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01235897" }, { "nct_id": "NCT01604772", "title": "Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Oral Cavity Adenoid Cystic Carcinoma", "Recurrent Salivary Gland Carcinoma", "Salivary Gland Adenoid Cystic Carcinoma", "Stage IVA Major Salivary Gland Cancer AJCC v7", "Stage IVA Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7", "Stage IVB Major Salivary Gland Cancer AJCC v7", "Stage IVB Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7", "Stage IVC Major Salivary Gland Cancer AJCC v7", "Stage IVC Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7" ], "interventions": [ { "name": "Akt Inhibitor MK2206", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2012-07-23", "completion_date": "2014-11-22", "has_results": true, "last_update_posted_date": "2019-05-01", "last_synced_at": "2026-10-04T06:36:20.518Z", "location_count": 51, "location_summary": "Lewes, Delaware • Newark, Delaware • Jacksonville, Florida + 36 more", "locations": [ { "city": "Lewes", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01604772" }, { "nct_id": "NCT01277757", "title": "Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Breast Carcinoma", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "Akt Inhibitor MK2206", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2011-03", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2018-12-19", "last_synced_at": "2026-10-04T06:36:20.518Z", "location_count": 5, "location_summary": "Boston, Massachusetts • New York, New York • Nashville, Tennessee + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01277757" }, { "nct_id": "NCT01306045", "title": "Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Carcinoma, Small Cell Lung", "Carcinoma, Thymic" ], "interventions": [ { "name": "AZD6244", "type": "DRUG" }, { "name": "MK-2206", "type": "DRUG" }, { "name": "Lapatinib", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" }, { "name": "Molecular Profiling", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 647, "start_date": "2011-02-08", "completion_date": "2024-07-17", "has_results": true, "last_update_posted_date": "2024-10-01", "last_synced_at": "2026-10-04T06:36:20.518Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01306045" }, { "nct_id": "NCT01425879", "title": "MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Adult Hepatocellular Carcinoma", "Localized Non-Resectable Adult Liver Carcinoma", "Recurrent Adult Liver Carcinoma", "Recurrent Gallbladder Carcinoma", "Stage IV Distal Bile Duct Cancer", "Stage IV Gallbladder Cancer", "Unresectable Extrahepatic Bile Duct Carcinoma", "Unresectable Gallbladder Carcinoma" ], "interventions": [ { "name": "Akt Inhibitor MK2206", "type": "DRUG" }, { "name": "Diagnostic Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2011-04", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2016-06-17", "last_synced_at": "2026-10-04T06:36:20.518Z", "location_count": 8, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01425879" }, { "nct_id": "NCT01705340", "title": "Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adenocarcinoma of the Gastroesophageal Junction", "HER2-positive Breast Cancer", "Male Breast Cancer", "Recurrent Breast Cancer", "Recurrent Esophageal Cancer", "Recurrent Gastric Cancer", "Stage IIIC Breast Cancer", "Stage IIIC Esophageal Cancer", "Stage IIIC Gastric Cancer", "Stage IV Breast Cancer", "Stage IV Esophageal Cancer", "Stage IV Gastric Cancer" ], "interventions": [ { "name": "Akt inhibitor MK2206", "type": "DRUG" }, { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "lapatinib ditosylate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2012-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-30", "last_synced_at": "2026-10-04T06:36:20.518Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01705340" }, { "nct_id": "NCT01714128", "title": "FES-PET for Patients Treated on NCI Protocol 8762", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Diagnostic Imaging ( 6α-[18F]fluoro-17β-estradiol (FES))", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2013-06", "completion_date": "2015-12", "has_results": false, "last_update_posted_date": "2021-10-25", "last_synced_at": "2026-10-04T06:36:20.518Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01714128" }, { "nct_id": "NCT01349933", "title": "Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Nasopharynx" ], "interventions": [ { "name": "Akt inhibitor MK2206", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2011-04", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2017-12-05", "last_synced_at": "2026-10-04T06:36:20.518Z", "location_count": 4, "location_summary": "Iowa City, Iowa • Rochester, Minnesota • Saint Louis Park, Minnesota + 1 more", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Saint Louis Park", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01349933" }, { "nct_id": "NCT01294306", "title": "MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenosquamous Lung Carcinoma", "Bronchioloalveolar Carcinoma", "Large Cell Lung Carcinoma", "Lung Adenocarcinoma", "Recurrent Non-Small Cell Lung Carcinoma", "Squamous Cell Lung Carcinoma" ], "interventions": [ { "name": "Akt Inhibitor MK2206", "type": "DRUG" }, { "name": "Erlotinib Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2011-02", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2016-11-29", "last_synced_at": "2026-10-04T06:36:20.518Z", "location_count": 7, "location_summary": "Beverly Hills, California • Duarte, California • Los Angeles, California + 4 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "South Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01294306" } ] }